Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study [Corrigendum]
Korol AR, Zborovska O, Kustryn T, et al. Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study. Clin Ophthalmol. 2017;11:1315–1320.
The Acknowledgement implies that Bayer Pharmaceuticals sponsored the study, this is not correct. The acknowledgment should state:
The authors take full responsibility for the scope, direction, and content of the manuscript, and have approved the submitted manuscript. Medical writing support was provided by Corey Eagan, MPH, of PAREXEL, and was funded by Bayer Pharmaceuticals.
Read the original article
© 2017 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.